A U.S. District Court in New York has approved the terms of a settlement between Del Global Technologies and its shareholders, dismissing all claims against Del and other defendants without any findings of liability or wrongdoing
A U.S. District Court in New York has approved the terms of a settlement between Del Global Technologies and its shareholders, dismissing all claims against Del and other defendants without any findings of liability or wrongdoing by any party, according to the company. Under the court-approved agreement, members of the class action will receive $2 million in cash and $2 million of subordinated promissory notes due in five years bearing interest at 6% per annum. Class action litigants will also receive 2.5 million shares of Del common stock with warrants to purchase one million shares of Del's common stock exercisable at $2 per share, expiring six years from the date of execution. Del Global develops and markets stationary and portable x-ray systems, as well as radio-frequency, mammography, and dental imaging systems. The company also makes high-voltage power conversion subsystems for medical and industrial applications.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).